Drugs / Transient CH505TF gp120
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03856996 | May 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transient CH505TF gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03856996 ↗ |
| Modality | Vaccine | “This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced by upstream stable and transient transfection” PMID 39671174 ↗ Apr 2025 |
| Route | Intramuscular | “by IM injection in the deltoid of the non-dominant arm” NCT03856996 ↗ |